owing pediatric market. The company intends to become a leading specialty pharmaceutical company by actively licensing, developing and commercializing late-stage products for specialty focused conditions. Arbor currently markets three products for varying otic conditions including XYLAREX®, ZINOTIC® and NEOTIC®, and also markets PEDIADERM™ HC COMPLETE KIT for atopic dermatitis, FLUORADAY® for fluoride supplementation, and RHINARIS® and SALTAIRE® for nasal hygiene.
For more information regarding Arbor Pharmaceuticals or any of its products, visit www.arborpharma.com or send email inquiries to email@example.com.
About JW Asset Management, LLC
JW Asset Management is a New York based fund manager for three investment partnerships. Jason Wild, a registered pharmacist, is the firm's founder and chief investment officer. JW Asset Management was founded in 1997 and has a strong history of finding opportunities within the specialty pharmaceutical sector. The firm is active in both the public and private equity markets.
About Signet Healthcare Partners
Signet Healthcare Partners was founded in 1998 and has a team that brings over 100 years of collective experience in the biopharmaceutical, medical device, private equity and investment banking businesses. Signet Healthcare has maintained its dedicated focus to diversified healthcare investing – primarily serving as lead investor to expansion stage companies engaged in specialty pharmaceuticals, medical devices and biopharmaceutical services.
About ARCH Healthcare Fund
ARCH Healthcare Page: 1 2 3 Related medicine technology :1
. DATATRAK Secures Safe Harbor Certification for EU and Switzerland2
. Quantum Signal and Delphinus Medical Technologies Awarded MEGA Funding to Expand in Ann Arbor Area3
. Arbor Pharmaceuticals Announces the Launch of Pediaderm(TM) HC Complete Kit - A Comprehensive Approach to the Management of Atopic Dermatitis4
. Harbor BioSciences to Receive Patent for Apoptone(R) Cancer Treatment5
. Hollis-Eden Announces Name Change to Harbor BioSciences, Inc. and Ticker Symbol Change to HRBR6
. Cold Spring Publishing, LLC, Changes Name to Harborside Press, LLC7
. Harborside Healthcare to Pay U.S. $1.375 Million to Resolve Allegations of Kickbacks and Sham Durable Medical Services8
. J. Craig Venter, Ph.D. Receives Double Helix Medal from Cold Spring Harbor Laboratory9
. Jiangbo Pharmaceuticals Announces Conference Call to Discuss Results for First Quarter Fiscal 201110
. Aires Pharmaceuticals, Inc. Completes $20M Equity Financing and Signs an Option Agreement with a Major Pharmaceutical Company11
. Access Pharmaceuticals Presents CobOral™ Insulin Research at 10th Annual Diabetes Technology Meeting on November 11-13, 2010